Gilead in 2023 and Beyond - J.P. Morgan Healthcare Conference 9 January 2023
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Gilead in 2023 and Beyond J . P. M o r g a n H e a l t h c a r e C o n f e r e n c e 9 January 2023
Forward-Looking Statements
Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead
cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those
relating to: the impact of the COVID-19 pandemic on Gilead’s business, financial condition and results of operations; the development, manufacturing and distribution of Veklury as a
treatment for COVID-19, including the uncertainty of the amount and timing of future Veklury sales, and Gilead’s ability to effectively manage the global supply and distribution of Veklury;
Gilead’s ability to achieve its anticipated full year 2022 financial results, including as a result of potential adverse revenue impacts from COVID-19 and potential revenues from Veklury;
Gilead’s ability to make progress on any of its long-term ambitions or strategic priorities laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its virology,
oncology and other programs; Gilead’s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements; Gilead’s ability to initiate, progress or complete
clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials and the risk that safety and efficacy data from
clinical trials may not warrant further development of Gilead’s product candidates or the product candidates of Gilead’s strategic partners; Gilead’s ability to submit new drug applications
for new product candidates or expanded indications in the currently anticipated timelines; Gilead’s ability to receive regulatory approvals in a timely manner or at all, and the risk that any
such approvals may be subject to significant limitations on use; Gilead’s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply
chain of Gilead’s products, including the risk that Kite may be unable to increase its manufacturing capacity, timely manufacture and deliver its products or produce an amount of supply
sufficient to satisfy demand for such products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a
larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the
risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; and other risks identified from
time to time in Gilead’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes
estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on
various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed
in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Gilead directs readers to its press releases, annual reports on Form 10-K,
quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation
Reform Act of 1995 for forward-looking statements.
The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All
forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other
than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.
Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, AMBISOME®, ATRIPLA®, BIKTARVY®,
CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, HEPSERA®, JYSELECA®, LETAIRIS®, ODEFSEY®, RANEXA®,
SOVALDI®, STRIBILD®, SUNLENCA®,TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA® and ZYDELIG®. This report
may also refer to trademarks, service marks and trade names of other companies.
2
Gilead in 2023
HIV Portfolio
Transformation Fast-Growing
Positioned for
Impact is Tangible Oncology Business
Continued Growth
Portfolio with quality, Leading HIV portfolio and Strong commercial
depth and breadth, strong poised to shape long-acting performance and clinical
financial performance, market following first momentum, including
and consistent execution. lenacapavir approvals. recent positive data.
3
Strong Progress in First Years of Transformation
Pipeline Bolstered with 81% Increase in 6 New Products with 9
M&A and Partnerships1 Pipeline Portfolio Approved Indications,
including 6 in Oncology2
Oncology
Virology 58
Inflammation
36
32
12
12 17
8 5
Q119 Q422
Illustration does not include opt-in assets
Four-year comparison reflects the time period January 2019 – December 2022 (except as otherwise noted). Projects are by asset-indication, excluding components of combo projects (HBV Cure, HIV Cure, lenacapavir projects)
1. Collaboration with Arcellx has been announced but not yet closed. Closing of transaction subject to regulatory clearances and other conditions. Agreement to acquire Tmunity has been announced but not yet closed. Closing of
4
transaction subject to regulatory clearances and other conditions. 2.Approved indications reflects first approval in a major market or new indications, does not include line extensions (e.g., expanded pediatric label). Count includes
conditional approval of Hepcludex (bulevirtide) by the European Medicines Agency in July 2020. Gilead acquired MYR / Hepcludex in December 2020.
Accelerating Progress with Strategic Priorities
Corporate Ambitions
Bring 10+ Transformative Be the Biotech employer Deliver Shareholder Value in a
Therapies to Patients by 2030 and partner of choice Sustainable, Responsible Manner
Key Strategic Priorities for 2023+
Maximize Near- Maximize Impact of Expand and Deliver
Term Revenue Long-Acting HIV on Oncology
Growth Therapies Programs
5
Maximize Near-Term Revenue Growth
Maintaining HIV Leadership as Growth Continues
• $7.5B Biktarvy Q322 YTD sales; +23% from Q321 YTD
$12.4B • ~45% U.S. share3 for Biktarvy in Q322; up 4% YoY from Q321
Q322 YTD HIV Revenue
• Biktarvy extends lead as #1 in new starts & switch in U.S.4
2033 • Biktarvy #1 in new starts in EU
Projected U.S. Biktarvy LOE1
• Impact of 2020 Truvada & Atripla LOEs now fully absorbed
• First U.S. and EU approvals for lenacapavir (Sunlenca)
2031
Projected U.S. Descovy LOE2 Expect HIV Revenue Growth Trend Through 2030
Note: Q322 YTD reflects Q1–Q3 2022 performance. Q321 YTD reflects Q1-Q3 2021 performance. YoY – Year-over-year growth for Q1-Q3 2022 vs Q1-Q3 2021. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) tablets. 1.
6 Estimated patent expiry corresponds to the latest expiring compound patent for one of the active ingredients in the single tablet regimen. 2. In September 2022, Gilead and five generic manufacturers (Lupin Ltd., Apotex Inc., Macleods
Pharma Ltd., Hetero Labs Ltd., and Cipla Ltd.) reached agreements to settle the patent litigation concerning patents that protect tenofovir alafenamide in our Descovy product. 3. Source: Monthly IQVIA NPA MD Regimen Market (NRTI
Market, excl. PrEP + 2-Drug Combos). 4. IQVIA NPA MD Weekly; National data includes PAP. 4. Reflects HIV PrEP TRxs from IQVIA NPA (retail & mail order).
Maximize Near-Term Revenue Growth
Accelerating Oncology Business with >$2B Annual Run-Rate
• ~65% YoY1 growth ~ 85% YoY1 growth
$1,040M $485M
•
• 96% manufacturing • Now reimbursed in
reliability Q322 YTD SALES2 16 countries Q322 YTD SALES2
Highlights & Anticipated Milestones Highlights & Anticipated Milestones
• Successful 2L R/R LBCL launch in U.S. in 2022 • sBLA for HR+/HER2- mBC accepted for priority
review; with PDUFA date in 1H23
• New manufacturing site in Maryland and viral
vector production at Oceanside approved in 2022 • MAA for HR+/HER2- mBC accepted for review
• 20+ countries with reimbursed product • Expect to initiate Phase 3 ASCENT-07 in endocrine-
resistant HR+/HER2- mBC in 2023
• Phase 2 ZUMA-24 in 2L LBCL outpatient interim
analysis in 1H23 • Phase 3 EVOKE-01 in NSCLC expected to be fully
enrolled in 1H23
Note: Yescarta (TRx coalesce) for IV infusion, Tecartus (brexucabtagene autoleucel) for IV infusion, and Trodelvy (sacituzumab govitecan-hziy) for injection. LBCL - large B cell lymphoma. MAA – Marketing Authorization Application. mBC
7 – metastatic breast cancer. NSCLC – non-small cell lung cancer. sBLA – Supplemental biologics license application. R/R – relapsed/refractory. 1. YoY – Year-over-year growth for Q1-Q3 2022 vs Q1-Q3 2021. 2. YTD22 reflects Q1–Q3 2022
performance.
Maximize Near-Term Revenue Growth
Reinvesting to Maximize Impact of COVID-19 Therapies
Today: Coming: Initiating 2 Pivotal Trials of Oral GS-5245
170+ Countries with
remdesivir access1
Standard-Risk High-Risk
~55% COVID patients seeking
care are standard-risk2
~45% COVID patients seeking
care are high-risk2
~12 million People treated
with remdesivir1 • Plan to enroll non-hospitalized • Enrolling non-hospitalized
patients without risk factors for patients at high-risk of
progression to severe disease3 progression to hospitalization4
• U.S. First Patient In (FPI) • Sites open in two countries with
U.S. hospitalized expected in Q123 additional expected shortly
~60% patients treated
for COVID
Dosing: GS-5245 one tablet, twice-daily for 5 days5
New Disclosure
Note: GS-5245 is an investigational product and is not approved anywhere globally; its safety and efficacy have not been established. 1. Represents number of treatments of Veklury or remdesivir made available by Gilead, its distributors and
8 voluntary licensees. 2. Estimated prevalence in the U.S. and EUCAN6; Source: Gilead Market Research, Komodo Claims Data (May-July 2022). 3. Defined as patients without underlying medical conditions associated with higher risk for severe
COVID-19 per CDC guidelines. 4. Defined as patients with 1+ (if unvaccinated) or 2+ (if vaccinated) risk factors, such as >50 years of age, cardiovascular disease, and chronic lung disease. 5. 350mg tablet twice-daily, no booster required.
Maximize Impact of Long-Acting HIV Therapies
Lenacapavir: Foundation of HIV Long-Acting Portfolio
2022
Approved for Heavily Prevention Pivotal Trials: Multiple Studies Ongoing
Treatment-Experienced PURPOSE-1 and PURPOSE-2 for Treatment
~1-2% of People Living with HIV
• Lenacapavir under • 10 potential partner agents
evaluation as monotherapy for lenacapavir
for PrEP
• 7 in clinical, 3 pre-clinical
• Expect to double
prevention utilization by • Testing multiple frequency
Approval1 in U.S. and EU and modality options
end of decade
Only Twice-Yearly HIV
Subcutaneous Option
9 1. Sunlenca should be taken with an optimized background regimen.
Note: Sunlenca is not approved for HIV prevention (PrEP) by any regulatory authority globally; its safety and efficacy have not been established for this use.
Maximize Impact of Long-Acting HIV Therapies
Diverse Pipeline of HIV Long-Acting Treatment Options
Modality Frequency Backbone Partner Modality Mix Expected to be
Once-Daily Lenacapavir Bictegravir Driven by Gilead Innovation
Phase 2/3 Combo
MTRs 100%
Oral Lenacapavir INSTI Oral LA Injectables
MTRs
Phase 1
1 Week
Lenacapavir NNRTI
Phase 1 Long-Acting
Orals &
Lenacapavir Islatravir
Phase 21 Injectables
Lenacapavir INSTI Inj.
Phase 1 Daily Orals
3 Months
Lenacapavir NRTI
Pre-IND
Injectable INSTI 1 Daily Orals
Lenacapavir
Pre-IND
6 Months
Lenacapavir INSTI 2
Pre-IND
0%
Updated Disclosure
Lenacapavir 2 bNAbs 2021 2030
New Disclosure Phase 1b POC Combo
Illustrative
Note: the combinations and dosing regimens shown are investigational and are not approved by any regulatory authority for any use; Their safety and efficacy are not established. Merck’s islatravir is an investigational agent and is not
10 approved by any regulatory authority for any use; its safety and efficacy are not established. 1. Lenacapavir + Islatravir oral combo is expected to commence in 1H 2023. bNabs - Broadly neutralizing antibody; IND – Investigational New
Drug; INSTI – Integrase strand transfer inhibitor; LA – Long-acting; MTR – Multi-tablet regimen. NNRTI – Non-nucleoside reverse transcriptase inhibitor; NRTI – Nucleoside reverse transcriptase inhibitor; POC – Proof of concept.Expand and Deliver on Oncology Programs
Oncology Portfolio Now Addresses Most Tumor Types
Solid Tumors1 Hematological Cancers2
Triple-
HR+ / HER2- Non-Small Acute
Negative Bladder Gastric and
Large B-cell Follicular
Breast Cell Lung Gastroesophageal Lymphocytic
Breast Cancer Junction Cancer Lymphoma Lymphoma
Cancer Cancer Leukemia
Cancer
Acute
Head and Prostate Small Cell Endometrial Colorectal Mantle Cell Myelodysplastic
Myeloid Syndrome
Neck Cancer Cancer Lung Cancer Cancer Cancer Lymphoma
Leukemia
Chronic
Pancreatic Cervical Ovarian Renal Cell Hepatocellular Multiple Rare B-Cell Lymphocytic
Cancer Cancer Cancer Carcinoma Carcinoma Myeloma Malignancies Leukemia
Approved or Accelerated Approval Under Review Clinical Programs Potential Diseases
Select Partnerships4:
1. Trodelvy received full approval for 2L metastatic triple-negative breast cancer in the US, EU, and Project Orbis countries; Trodelvy received accelerated approval for 2L metastatic urothelial cancer in the US. 2. Yescarta is approved for
11 3L+ relapsed/refractory (R/R) large B-cell lymphoma in the US and EU, among others, and received accelerated approval in 3L+ R/R follicular lymphoma in the US. Tecartus was granted accelerated approval for R/R mantle cell lymphoma
in the US and EU, and full approval for R/R adult acute lymphoblastic leukemia.4. Collaboration with Arcellx has been announced but not yet closed. Closing of transaction subject to regulatory clearances and other conditions.Expand and Deliver on Oncology Programs
Trodelvy is a Cornerstone of our Oncology Program
Solid Tumors1
Triple-
Negative
Breast
Bladder
Cancer
HR+ / HER2-
Breast
Cancer
Non-Small
Cell Lung
Cancer
Gastric and
Gastroesophageal
Junction Cancer
10 Total ongoing trials2
Cancer
Head and Prostate Small Cell Endometrial Colorectal
6 On-going Phase 3 trials2
Neck Cancer Cancer Lung Cancer Cancer Cancer
5 Active combination trials2
Pancreatic Cervical Ovarian Renal Cell Hepatocellular
Cancer Cancer Cancer Carcinoma Carcinoma
>1.3M Addressable patients3
Approved or Accelerated Approval Under Review Clinical Programs Potential Diseases
Select Partnerships:
1. Trodelvy received full approval for 2L+ metastatic triple-negative breast cancer in the US, EU, and Project Orbis countries; Trodelvy received accelerated approval for 2L+ metastatic urothelial cancer in the US. 2. Industry-sponsored
12 clinical phase trials (excluding ISRs and regional bridging studies) 3. Source: Custom Equinox Epi Model of potentially addressable patient population; 2030 estimates in the US and Europe. Includes epi based on addressable population in
trials that have already initiated, which excludes colorectal, pancreatic and cervical cancer.Expand and Deliver on Oncology Programs
Comprehensive Trodelvy Breast Cancer Program
Addressable Addressable
TNBC Population1
HR+/HER2- Population1
Neo- NeoSTAR (DCFI Collab) Neo-
~11K NeoSTAR (DCFI Collab) ~44K
adjuvant Ph3 Low Risk (WSG Collab) adjuvant
ASCENT-05
Adjuvant2 ~40K Adjuvant SASCIA (GBG Collab) ~280K
SASCIA (GBG Collab)
ASCENT-03
1L ASCENT-04 ~24K 1L
Magrolimab (NCT04958785)3 ASCENT-07 ~210K
2L
2L ASCENT
FDA and EMA Approvals in 2L mTNBC ~26K
3L+ Magrolimab (NCT04958785)3 3L+ TROPiCS-02 ~107K4
4 >700K
Ongoing Phase 3 Trials in Addressable Patients1 Across
Breast Cancer Breast Cancer by 2030
13 1. Patient segment size estimates reflect 2030 incidence rates in breast cancer. Source: Custom Epi Model by Equinox for US/EU5. 2. Post-neoadjuvant, in patients without pCR. 3. NCT04958785 cohort 1 includes 1L patients
with PD-L1- mTNBC and cohort 2 includes 2L patients with mTNBC (must have had prior PD-L1 inhibitor if PD-L1+). 4. Estimate approximately 25K patients have had ET, CDK4/6i, and 2 prior chemotherapy in the EU5/USExpand and Deliver on Oncology Programs
Trodelvy Could Address Significant Unmet Need
When Approved1 Future
First and only TROP2 ADC to demonstrate Potential to displace chemotherapy
OS benefit in endocrine resistant, chemo in earlier treatment lines2
treated patients with HR+/HER2- mBC
HR+/HER2- mBC
~317K addressable patients3
Chemotherapy5
Chemotherapy4 4-6 or 5-10
HER2-low Months HER2 ADC5 Months Chemotherapy
mPFS mPFS or
~65% of HR+ BC
ASCENT-07 ASCENT-07
28-44
Endocrine Tx Months
6 4-6
+/- CDK4/6i Tx Months
mPFS mPFS
Note: No data available on the use of Trodelvy
HER2 IHC-0 2 Chemotherapies4,5 9-11
after HER2 ADC
~35% of HR+ BC Months
ASCENT-07 TROPiCS-02
mPFS
Treatments Received
Disclaimer: mPFS ranges represent estimates based on published clinical trial data. The data do not represent the duration of treatment, efficacy of the treatment used sequentially, or outcomes intended for cross-trial comparisons.
1. Trodelvy for HR+/HER2- mBC is investigational and is currently under review by FDA. It is not guaranteed that FDA will approve Trodelvy for this use. sBLA for pre-treated HR+/HER2- mBC submitted; PDUFA action date 1Q23. 2. Chemotherapy is expected to remain a
14 treatment option for select patients.3. Patient segment size reflect 2030 incidence rates in HR+/HER2- metastatic breast cancer. Source: Custom Epi Model by Equinox for US/EU5 4. mPFS of 4-6 months for chemotherapy based on the Ph3 OlympiAD, EMBRACA, and
TNT studies. 5. Enhertu: mPFS of 5 months for chemotherapy and 10 months for Enhertu based on the DESTINY-Breast04 Trial. 6. mPFS of 4 months for chemotherapy and 6 months for Trodelvy based on TROPiCS-02 study. ADC – antibody drug conjugate. mBC –
metastatic breast cancer. mPFS – median progression free survival. OS – overall survival. Tx – treatment.Expand and Deliver on Oncology Programs
Comprehensive Lung Clinical Program Underway
Addressable
Gilead Asset External Asset Studies Population1
8 Ongoing NSCLC trials2
Stage III Domvanalimab Durvalumab PACIFIC-8 ~28K
unresectable
6 Ongoing combination trials2
Domvanalimab
Trodelvy
Chemotherapy
ARC-7
ARC-103
Pembrolizumab
Etrumadenant
DOM EDGE Lung4
Pembrolizumab
8
1L
Trodelvy
ZIM EVOKE-02 ~190K
Stage IV
Investigational assets2 Quemliclustat
ETRUMA EVOKE-033,4
Zimberelimab
QUEMLI STAR-1213
VELOCITY Lung
Data readout for the pivotal Ph3 Domvanalimab Chemotherapy EDGE Lung4
2L+
EVOKE-01 in 2-3L mNSCLC (IO/
Etrumadenant ELEVATE Lung5
Magrolimab EVOKE-013 ~120K
estimated by 2024 chemo
exposed) Trodelvy TROPiCS-03
Zimberelimab VELOCITY Lung4
Note: Arcus is leading and operationalizing ARC-7, ARC-10, and EDGE Lung Platform. EVOKE-02 and EVOKE-03 are done in collaboration with Merck, with Merck operationalizing EVOKE-03. Astra Zeneca is operationalizing PACIFIC-8 in
15 collaboration with Arcus and Gilead. Source: Johnson et al., 2022 – ASCO December Plenary Session. Dom – domvanalimab. Etruma – etrumadenant. IA4 – interim analysis 4. Quemli – quemliclustat. Zim – zimberelimab. 1. Source:
Based on 2030 Estimates from a Custom Epi Model by Equinox for the US/EU5. 2. Industry-sponsored clinical phase trials (excluding ISRs and regional bridging studies). 3. Phase 3 program. 4. FPI expected in 2023. 5. ELEVATE Lung & UC
trial is listed as NCT04827576 on clinicaltrials.govExpand and Deliver on Oncology Programs
ARC-7: Dom Shows Potential to be Best-in-Class TIGIT
Doublet and triplet showed
clinically meaningful efficacy
Potentially differentiated safety
profile
Potential for novel and
differentiated IO combinations
ARC-7 Interim Analysis 4
1L mNSCLC Stage III NSCLC Gastric / Esophageal /
ARC-10 & STAR-121 PACIFIC-8 GEJ Adenocarcinoma
~190K addressable population1 ~28K addressable population1 STAR-221
~70K addressable population1
Note: Domvanalimab is an investigational product and is not approved anywhere globally; its safety and efficacy have not been established
16 1. Based on 2030 Estimates from a Custom Epi Model by Equinox for the US/EU5. Dom - domvanalimab
Source: Johnson, et al. ASCO Plenary Session. 2022Expand and Deliver on Oncology Programs
Exploring Full Potential of Magrolimab
Solid Tumors Hematological Cancers
Triple-
Non-Small Gastric and Acute
Negative Bladder HR+ / HER2- Large B-cell Follicular
Cell Lung Gastroesophageal Lymphocytic
Breast Cancer Breast Cancer Junction Cancer Lymphoma Lymphoma
Leukemia
Cancer
Cancer
Acute
Head and Prostate Small Cell Endometrial Colorectal Mantle Cell Myelodysplastic
Myeloid Syndrome
Neck Cancer Cancer Lung Cancer Cancer Cancer Lymphoma
Leukemia
Chronic
Pancreatic Cervical Ovarian Renal Cell Hepatocellular Multiple Rare B-Cell Lymphocytic
Cancer Cancer Cancer Carcinoma Carcinoma Myeloma Malignancies Leukemia
Approved or Accelerated Approval Under Review Clinical Programs
8 Trials Achieved FPI
in 2021-22 4 Indications with
Phase 1/2 Data 2 Trials Completed
Enrollment in 2022
17 Note: FPI – first patient inExpand and Deliver on Oncology Programs
Advancing and Investing in Magrolimab Programs
Broad program across hematological cancers and solid tumors
Pivotal Trials
Phase 2
• No new safety signals identified
1L HR MDS 1L TP53m AML 1L Unfit AML
Trial ENHANCE ENHANCE-2 ENHANCE-3
• Gilead remains blinded to the data
Stage Phase 3 Phase 3 Phase 3
Fully enrolled FPFV FPFV
• Continued commitment to the Status
Q3 2022 Q4 2021 Q3 2022
potential for magrolimab magro + aza +
Combination magro + aza magro + aza
venetoclax
Next Update1 2H23 2H24 2H24
Following First Interim Analysis, ENHANCE Study is Ongoing
Note: AML – acute myeloid leukemia; FPFV – first patient first visit; HR-MDS - high risk myelodysplastic syndrome. Magrolimab is an investigational product and is not approved anywhere globally; its safety and efficacy have not been
18
established 1. Expected update timing is provisional and reflects potential data readouts for interim analyses which are event-driven; studies are powered for final analyses.Expand and Deliver on Oncology Programs
Cell Therapy Portfolio Continues to Expand
Solid Tumors Hematological Cancers
Triple-
Non-Small Gastric and Acute
Negative Bladder HR+ / HER2- Large B-cell Follicular
Cell Lung Gastroesophageal Lymphocytic
Breast Cancer Breast Cancer Junction Cancer Lymphoma Lymphoma
Cancer1 Leukemia
Cancer1
Acute
Head and Neck Prostate Small Cell Endometrial Colorectal Mantle Cell Myelodysplastic
Myeloid Syndrome
Cancer Cancer Lung Cancer Cancer Cancer Lymphoma
Leukemia
Chronic
Pancreatic Cervical Ovarian Renal Cell Hepatocellular Multiple Rare B-Cell Lymphocytic
Cancer1 Cancer Cancer1 Carcinoma Carcinoma Myeloma2 Malignancies Leukemia
Approved or Accelerated Approval Under Review Clinical Programs1 Potential Diseases
10 Clinical stage programs3 16 Early stage assets3 9 Strategic partnerships
1. These clinical programs are led by Tmunity which is being acquired by Kite. The transaction is expected to close in Q123, subject to regulatory clearances and other conditions.
19 2.This clinical program is currently led by Arcellx, and will transition to Kite when the collaboration agreement closes (expected in Q123, subject to regulatory clearances and other
conditions).Count includes partnered assets but does not include potential partner opt-in programs.Capital Priorities Unchanged: Returned $5B+ in 2022
$3.7B Continue to invest in our business and R&D pipeline
Dividends Paid in FY22 while managing expenses
Continue ordinary course partnerships and business
$1.5B development transactions
Debt Repaid in FY22 Grow our dividend
$1.4B Repurchase shares to offset dilution and
opportunistically reduce share count
Shares Repurchased in FY22
18.9M shares at average $73.76
20 Note: Gilead’s results for the full-year ended December 31, 2022 have not been finalized and are subject to Gilead’s financial statement closing procedures. Actual results could differ from the preliminary estimates described above.Gilead in 2023
Transformation HIV Positioned for Fast-Growing
Impact is Tangible Continued Growth Oncology Business
Portfolio with quality, Leading HIV portfolio and Strong commercial
depth and breadth, strong poised to shape long-acting performance and clinical
financial performance, market following first momentum, including
and consistent execution. lenacapavir approvals. recent positive data.
21Gilead in 2023 and Beyond: Q&A J . P. M o r g a n H e a l t h c a r e C o n f e r e n c e 9 January 2023
You can also read
